In a phase III trial, advanced HCC patients were randomly assigned to receive either cabozantinib (TKI) 40 mg once per day plus atezolizumab (ICI, anti-PD-L1 antibody) 1200 mg on the first day of every 21-day cycle, or sorafenib (TKI) 400 mg twice a day until tumor progression [86]. The gene discussed is CD274; the disease is neoplasm.